drugset
drugset / Trial / NCT04631549

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

NCT04631549 ↗

Phase 1 Unknown 24 enrolled Jiangsu HengRui Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to investigate SHR3680 in participants with different levels of liver function

Timeline

Start
2021-02-03
Primary completion
2023-07
Completion
2023-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rezvilutamide Small molecule — Oral

Indications

No indication recorded.